Rubraca
Total Payments
$47.4M
Transactions
26,320
Doctors
5,501
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $976,863 | 214 | 52 |
| 2023 | $1.9M | 204 | 6 |
| 2022 | $2.6M | 952 | 492 |
| 2021 | $6.4M | 2,221 | 700 |
| 2020 | $11.2M | 4,058 | 1,489 |
| 2019 | $16.6M | 8,211 | 2,576 |
| 2018 | $6.6M | 7,203 | 2,189 |
| 2017 | $1.1M | 3,257 | 1,757 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41.8M | 6,562 | 88.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 749 | 4.8% |
| Consulting Fee | $1.2M | 517 | 2.6% |
| Travel and Lodging | $598,437 | 1,324 | 1.3% |
| Current or prospective ownership or investment interest | $554,970 | 6 | 1.2% |
| Food and Beverage | $448,198 | 15,735 | 0.9% |
| Grant | $350,000 | 6 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $132,225 | 49 | 0.3% |
| Education | $33,102 | 1,370 | 0.1% |
| Royalty or License | $16,250 | 1 | 0.0% |
| Honoraria | $535.00 | 1 | 0.0% |
Payments by Type
Research
$41.8M
6,562 transactions
General
$5.6M
19,758 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Clovis Oncology, Inc. | $11.1M | 0 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Clovis Oncology, Inc. | $5.7M | 1 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | Clovis Oncology, Inc. | $5.2M | 0 |
| Lung MAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer Sub-Study S1900A A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer | Clovis Oncology, Inc. | $4.0M | 0 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) | Clovis Oncology, Inc. | $2.6M | 0 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | pharmaand GmbH | $1.9M | 0 |
| A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | Clovis Oncology, Inc. | $1.8M | 0 |
| A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) | Clovis Oncology, Inc. | $998,799 | 0 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | pharmaand GmbH | $979,480 | 0 |
| A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer | Clovis Oncology, Inc. | $870,041 | 0 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Clovis Oncology, Inc. | $797,402 | 0 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Clovis Oncology, Inc. | $727,844 | 1 |
| A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Clovis Oncology, Inc. | $532,954 | 0 |
| A PHASE 2, OPEN LABEL STUDY OF MAINTENANCE RUCAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE ADVANCED PANCREATIC CANCER AND A KNOWN DELETERIOUS GERMLINE OR SOMATIC BRCA1/2 OR PALB2 MUTATION | Clovis Oncology, Inc. | $522,631 | 0 |
| Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | Clovis Oncology, Inc. | $450,033 | 0 |
| A Phase II study with a safety lead-in of nivolumab in combination with bevacizumab or in combination with bevacizumab and rucaparib for the treatment of relapsed epithelial ovarian, fallopian tube or peritoneal cancer | Clovis Oncology, Inc. | $336,674 | 0 |
| Phase 1: Rucaparib and postoperative Radiotherapy in triple negative breast cancer | Clovis Oncology, Inc. | $287,680 | 0 |
| A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy | Clovis Oncology, Inc. | $230,144 | 0 |
| ENDOBARR: An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma | Clovis Oncology, Inc. | $213,972 | 0 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | Clovis Oncology, Inc. | $197,154 | 1 |
Top Doctors Receiving Payments for Rubraca
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Oklahoma City, OK | $42.2M | 6,609 |
| , MD | Specialist | Boston, MA | $660,619 | 17 |
| , MD | Obstetrics & Gynecology | Hershey, PA | $211,247 | 165 |
| , MD | Obstetrics & Gynecology | Detroit, MI | $185,931 | 166 |
| , MD | Obstetrics & Gynecology | San Jose, CA | $174,975 | 165 |
| , MD | Gynecologic Oncology | Phoenix, AZ | $174,486 | 187 |
| , M.D | Gynecologic Oncology | Philadelphia, PA | $149,235 | 137 |
| Chirag Shah | Gynecologic Oncology | Seattle, WA | $122,960 | 111 |
| , MD | Obstetrics & Gynecology | Phoenix, AZ | $121,610 | 124 |
| , MD | Obstetrics & Gynecology | Stanford, CA | $108,194 | 89 |
| , MD | Gynecologic Oncology | Tampa, FL | $107,238 | 98 |
| , MD | Medical Oncology | Jackson, MS | $104,255 | 79 |
| , MD | Gynecologic Oncology | East Syracuse, NY | $98,679 | 91 |
| , MD | Gynecologic Oncology | Pittsburgh, PA | $89,402 | 98 |
| , M.D | Gynecologic Oncology | Indianapolis, IN | $84,711 | 68 |
| , MD | Gynecologic Oncology | Scottsdale, AZ | $82,168 | 80 |
| , D.O | Obstetrics & Gynecology | Kansas City, MO | $80,867 | 85 |
| , M.D | Gynecologic Oncology | Atlanta, GA | $76,696 | 68 |
| , MD | Gynecologic Oncology | Fort Myers, FL | $76,252 | 71 |
| , M.D | Obstetrics & Gynecology | San Diego, CA | $75,221 | 64 |
| , MD | Gynecologic Oncology | Covington, LA | $72,728 | 95 |
| , MD | Gynecologic Oncology | Orlando, FL | $71,312 | 76 |
| , M.D | Gynecologic Oncology | Orange, CA | $66,860 | 74 |
| , M.D | Obstetrics & Gynecology | Cleveland, OH | $60,405 | 73 |
| , M.D | Gynecologic Oncology | Chandler, AZ | $59,620 | 65 |
Ad
Manufacturing Companies
- Clovis Oncology, Inc. $44.5M
- pharmaand GmbH $2.9M
Product Information
- Type Drug
- Total Payments $47.4M
- Total Doctors 5,501
- Transactions 26,320
About Rubraca
Rubraca is a drug associated with $47.4M in payments to 5,501 healthcare providers, recorded across 26,320 transactions in the CMS Open Payments database. The primary manufacturer is Clovis Oncology, Inc..
Payment data is available from 2017 to 2024. In 2024, $976,863 was paid across 214 transactions to 52 doctors.
The most common payment nature for Rubraca is "Unspecified" ($41.8M, 88.1% of total).
Rubraca is associated with 20 research studies, including "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)" ($11.1M).